Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase

PHASE3CompletedINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

March 31, 2013

Conditions
Ulcerative Colitis in Remission
Interventions
DRUG

Asacol®

400 mg tablets

DRUG

Mesalazine

400mg tablets

Trial Locations (1)

Unknown

Shanghai Hospital, Shanghai

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Zeria Pharmaceutical

INDUSTRY

lead

Tillotts Pharma AG

INDUSTRY